MDxHealth S.A.
NASDAQ:MDXHMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $57.59M
- Beta
- 0.38
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$0.58
Volume 0.65M
Average 4.27M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
MDxHealth S.A.
NASDAQ:MDXH
Intrinsic Alpha fair value
Locked
Current Price
$0.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +42.8% | +11.0% (4yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +42.8% over three years. Forward estimates point to Revenue at +11.0% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. NASDAQ:ACRS | $512.97M | $3.49 | Not rated | -8.2 | +42.28% |
NeoGenomics, Inc. NASDAQ:NEO | $443.24M | $17.25 | Not rated | -2.9 | +48.74% |
Assembly Biosciences, Inc. NASDAQ:ASMB | $418.82M | $20.57 | Not rated | -64.4 | -41.08% |
Zura Bio Limited NASDAQ:ZURA | $410.15M | $4.28 | Not rated | -5.5 | -75.06% |
Shoulder Innovations, Inc. NYSE:SI | $382.44M | $18.37 | Not rated | -8.4 | +46.04% |
Immuneering Corporation NASDAQ:IMRX | $235.50M | $3.64 | Not rated | -3.6 | -51.19% |
Exagen Inc. NASDAQ:XGN | $207.37M | $8.56 | Not rated | -5.2 | -50.70% |
Quanterix Corporation NASDAQ:QTRX | $145.19M | $3.07 | Not rated | -1.5 | -64.68% |
Stereotaxis, Inc. AMEX:STXS | $105.21M | $1.05 | Not rated | -8.3 | -57.76% |
SANUWAVE Health, Inc. NASDAQ:SNWV | $44.47M | $5.17 | Undervalued | 5.0 | -81.55% |
Continue the stock analysis
Jump to another research area for this company.